These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34182038)

  • 21. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
    Nie J; Li Q; Wu J; Zhao C; Hao H; Liu H; Zhang L; Nie L; Qin H; Wang M; Lu Q; Li X; Sun Q; Liu J; Fan C; Huang W; Xu M; Wang Y
    Emerg Microbes Infect; 2020 Dec; 9(1):680-686. PubMed ID: 32207377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
    Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
    Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.
    Verma D; Church TM; Swaminathan S
    J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
    Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
    Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus.
    DeBarros K; Khan M; Coleman M; Bond VC; Floyd V; Gbodossou E; Diop A; Krumpe LRH; O'Keefe BR; Powell MD
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
    Hoffmann M; Sidarovich A; Arora P; Krüger N; Nehlmeier I; Kempf A; Graichen L; Winkler MS; Niemeyer D; Goffinet C; Drosten C; Schulz S; Jäck HM; Pöhlmann S
    mBio; 2022 Jun; 13(3):e0036422. PubMed ID: 35467423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants.
    Mendon N; Ganie RA; Kesarwani S; Dileep D; Sasi S; Lama P; Chandra A; Sirajuddin M
    J Biol Chem; 2023 Jan; 299(1):102732. PubMed ID: 36423687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
    Li J; Wang P; Tracey KJ; Wang H
    Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.
    Thimmiraju SR; Villar MJ; Kimata JT; Strych U; Bottazzi ME; Hotez PJ; Pollet J
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
    Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
    van Breemen RB; Muchiri RN; Bates TA; Weinstein JB; Leier HC; Farley S; Tafesse FG
    J Nat Prod; 2022 Jan; 85(1):176-184. PubMed ID: 35007072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
    Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
    Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.